{"bills":[{"photos":{"featured":"https://assets.causes.com/bill/photo/hr2430-115/featured_fda-reauthorization-act-of-2017-1501775680.jpg","featured_large":"https://assets.causes.com/bill/photo/hr2430-115/featured_large_fda-reauthorization-act-of-2017-1501775680.jpg","shareable":"https://n.causes.com/share-images/bills/hr2430-115.png"},"introduced_on":"2017-05-16","title_override":"Should the FDA’s Drug User Fees on Drug Manufacturers be Reauthorized?","summary_override":"

This bill would reauthorize the Food and Drug Administration’s (FDA) authority to collect user fees from the makers of prescription brand drugs, medical devices, generic drugs and biosimilars, and several other FDA programs through 2022. Under current law, user fee agreements — which provide a substantial amount of the FDA’s funding — are set to expire on September 30, 2017.

Drug Fees

This section of the bill would reauthorize the FDA’s authority to collect and credit fees related to drugs. It would be able to collect fees at a higher level and restructure the fees to reduce administrative burdens. The fee structure would being divided evenly divided between facility fees, application fees, and product fees to being 20 percent application fees and 80 percent program fees for approved products. The base fee amount would rise from over $718 million to more than $878 million.

The existing reauthorization process would be maintained by this bill, under which the Dept. of Health and Human Services (HHS) would provide recommendations to Congress by January 15, 2022 after holding public hearings. The FDA would be authorized to collect fees until October 1, 2022 and would need to submit performance and financial reports to Congress on January 31, 2023.

Medical Device Fees

This section would reauthorize the FDA’s authority to collect and credit fees relating to medical devices. It would allow for new authority to collect fees for de novo classification requests. The target base fee amounts would be updated, with FY2017 set at over $130 million, FY2018 increased to about $183 million, and more than $213 million in FY2022. The FDA would be authorized to collect fees until October 1, 2022 and would need to submit performance and financial reports to Congress on January 31, 2023.

Generic Drug Fees

This section would reauthorize the FDA’s authority to collect and credit fees relating to generic drugs. Fees for prior approval supplements would be eliminated, and a generic drug applicant program fee would be established that requires manufacturers with more approved applications to pay a greater share of the fee. One-third of the total revenue would come from generic drug application fees, 20 percent will come from generic drug facility fees, seven percent will come from active pharmaceutical ingredient facility fees, and 35 percent will come from the new generic drug applicant program fee.

The base fee amount would rise from $299 million in FY2017 to $493 million in FY2018. The FDA would be authorized to collect fees until October 1, 2022 and would need to submit performance and financial reports to Congress on January 31, 2023.

Biosimilar Product Fees

This section would reauthorize the FDA to collect and credit fees for biosimilar products. A fee structure would established that has an initial fee during clinical trials, an annual development for new biosimilars, and a program fee for sponsors of approved biosimilars. The base fee amount would increase from $20 million to $45 million. The FDA would be authorized to collect fees until October 1, 2022 and would need to submit performance and financial reports to Congress on January 31, 2023.

","official_title":"To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.","short_title":"FDA Reauthorization Act of 2017","popular_title":null,"short_summary":"(This measure has not been amended since it was passed by the House on July 12, 2017. The summary of that version is repeated here.)\n\nFDA Reauthorization Act of 2017\n\nTITLE I--FEES RELATING TO DRUGS\n\nPrescription Drug User Fee Amendments of 2017\n\n(Sec. 102) This bill amends the Federal Food, Drug, and Cosmetic Act to extend through FY2022 and revise Food and Drug Administration (FDA) user fees for brand name drugs. User fees are eliminated for supplemental new drug applications and drug manufacturing facilities.\n\nA prescription drug program fee replaces the prescription drug product fee. This annual fee is assessed on a new drug application holder for each approved drug for up to five drugs.\n\nThe total user fee revenue amount is adjusted annually for changes in review process capacity needs, to provide for operational reserves, and for additional direct costs. Eighty percent of revenues must be generated by prescription drug program fees, with the remainder from application fees.\n\n(Sec....","summarized":true,"cost":null,"cost_commentary":"The CBO estimates that enacting this bill would reduce the aggregate deficit by $72 million over the 2018-2027 period.","impact":"Manufacturers of drugs, medical devices, and biosimilar products; and the FDA.","argument_for":"This bipartisan reauthorization bill will ensure the FDA has the resources it needs through continued access to user fees assessed on manufacturers of drugs, medical devices, and biosimilar products.","argument_against":"The FDA doesn’t need the funding it generates by its user fee programs that collects fees from manufacturers of drugs, medical devices, and biosimilar products.","bill_type":"hr","published":true,"type":"FederalBill","id":"hr2430-115","bill_id":"hr2430-115","formal_id":"H.R. 2430","chamber":"house","congress":115,"last_action_at":"2017-08-18T00:00:00.000Z","active":true,"enacted":true,"enacted_at":"2017-08-18","vetoed":false,"last_vote_at":"2017-08-03T00:00:00.000Z","debated_on":null,"congress_url":"https://www.congress.gov/bill/115th/house-bill/2430","plain_text_url":"https://www.gpo.gov/fdsys/pkg/BILLS-115hr2430enr/html/BILLS-115hr2430enr.htm","shareable_image_url":"https://n.causes.com/share-images/bills/hr2430-115.png","congress_full_text_url":"https://www.congress.gov/bill/115th/house-bill/2430/text","is_current_congress":false,"last_version_on":"2017-08-05","related_bill_ids":["s934-115","hr2376-115","s1062-115","s1093-115","hr1652-115","s670-115","s1048-115","s1069-115"],"progress":"Enacted","house_passage_result":true,"senate_passage_result":true,"position_count":190,"committees":[{"name":"Committee on Energy and Commerce","chamber":"house","committee_id":"HSIF","subcommittee":false},{"name":"Health","chamber":"house","committee_id":"HSIF14","subcommittee":true}],"links":{"rollCalls":"/api/roll_calls?bill_id=hr2430-115","details":"/api/bills/hr2430-115/details","sharingMessage":"/api/sharing_messages/hr2430-115","positionsFor":"/api/bills/hr2430-115/positions/for","positionsAgainst":"/api/bills/hr2430-115/positions/against"},"upcoming":false,"cosponsors_count":3,"slug":"hr2430-115-fda-reauthorization-act-of-2017","latest_chamber_votes_id":"hr2430-115","official_url":null,"target_video":true,"following":false,"vote_count":2452,"yea_vote_count":1724,"nay_vote_count":719,"passed_house":true,"passed_senate":true,"vote_id":null,"my_position_id":null,"topic_ids":["health"],"issue_ids":["health"],"sponsor_id":206}],"votes":[],"issues":[{"id":"health","name":"Health","slug":"health","description":"Federal legislation around Health, encompassing: the Affordable Care Act, Medicare, Research into diseases (Cancer, HIV/Aids, Ebola), Drug safety, Hospital care and prescription drugs.","page_title":"Health Related US Federal legislation, including Medicare, ACA, and research - Vote on Bills, Stay informed, Hold Your Reps Accountable","icons":{"black":"https://assets.causes.com/issue/icon/health/black_health-1429042037.svg","grey":"https://assets.causes.com/issue/icon/health/grey_health-1429042037.svg","white":"https://assets.causes.com/issue/icon/health/white_health-1429042037.svg"},"cover_image_url":null,"is_following":false}],"users":[{"name":"Chris","vote_count":578,"photos":{"large":"https://graph.facebook.com/10109078613313080/picture?width=150&height=150","small":"https://graph.facebook.com/10109078613313080/picture?width=75&height=75","tiny":"https://graph.facebook.com/10109078613313080/picture?width=20&height=20","facebook":"https://graph.facebook.com/10109078613313080/picture"},"links":{"following":"/api/users/GWdeLrVZ/following","followers":"/api/users/GWdeLrVZ/followers"},"about_me":null,"twitter_id":null,"facebook_id":null,"youtube_id":null,"google_plus_id":null,"website":null,"slug":null,"issue_count":6,"is_following":null,"influence_score":1190,"influence_level":30,"follower_count":24,"following_count":0,"position_count":428,"id":"GWdeLrVZ","partner_id":null}],"bill_position":{"flagged":false,"id":"e306d7f5-283c-4adf-8e0a-8bfe327ac4bd","argument_for":"The pharmaceutical companies who will profit to the number of billions of dollars a year can afford to pay for oversight and regulation to make sure that the drugs they sell are safe and regulated. It is the least they can do considering they have played a significant role in creating and maintaining the devastating opioid epidemic in this country. ","argument_against":null,"show_argument_for":true,"show_argument_against":false,"upvote_count":0,"upvotes_for_count":0,"upvotes_against_count":null,"has_upvoted":false,"endorsement_count":0,"links":{"self":"https://www.causes.com/positions/e306d7f5-283c-4adf-8e0a-8bfe327ac4bd"},"body":"The pharmaceutical companies who will profit to the number of billions of dollars a year can afford to pay for oversight and regulation to make sure that the drugs they sell are safe and regulated. It is the least they can do considering they have played a significant role in creating and maintaining the devastating opioid epidemic in this country. ","stance":"yea","created_at":"2017-08-17T04:28:36.526Z","shareable_image_url":"https://n.causes.com/share-images/positions/e306d7f5-283c-4adf-8e0a-8bfe327ac4bd.png","note_color":null,"note_text":null,"bill_id":"hr2430-115","user_id":"GWdeLrVZ","endorser_ids":[]}}

Like Causes?

Chris

Should the FDA’s Drug User Fees on Drug Manufacturers be Reauthorized?